Biosimilar Antibodies
| Cat.No. | Product Name | Information | Isotype |
|---|---|---|---|
| A2703 | Bapotulimab (Anti-ILDR2) | Bapotulimab (Anti-ILDR2) is a fully human immunoglobulin G2 (IgG2) monoclonal antibody against the immune checkpoint immunoglobulin-like domain containing receptor 2 (ILDR2; Chromosome 1 Open Reading Frame 32; C1orf32), with potential immune checkpoint inhibitory and antineoplastic activities. MW : 145.24 kD. | Human IgG2SA |
| A2959 | Anti-IL-18 (ABT-325) | Anti-IL-18 (ABT-325) is a humanised monoclonal antibody targeted against Interleukins-18 (IL-18) with the potential to treat autoimmune diseases. MW: 146.28 KD. | Human IgG1 |
| A2704 | Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) | Anti-Integrin aVb6 (ITGAV & ITGB6) (STX-100) is a humanised monoclonal antibody directed against the alpha v beta 6 (αvβ6) Integrin. It has a potential to be used in research on Idiopathic Pulmonary Fibrosis (IPF). MW: 144.88 kD. | Human IgG1 |
| A2960 | Anti-IL-1b (CDP484) | Anti-IL-1b (CDP484) is an antibody targeted against Interleukin-1beta (IL-1b), a cytokine that initiates inflammatory cascades. MW: 145.74 KD. | Human IgG1 |
| A2961 | Anti-F8 / Factor VIII | Anti-F8 / Factor VIII is a monoclonal IgG anti-factor VIII antibody that hydrolyses FVIII in acquired haemophilia. MW: 145.14 KD. | Human IgG1 |
| A2706 | Anti-CXCR3 / GPR9 / CD183 | Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)). It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD. | Human IgG1 |
| A2962 | Melrilimab (Anti-IL-1RL1 / ST2 / IL-33R) | Melrilimab (anti-IL-1RL1/ ST2 / IL-33R) is an anti-ST2 (IL-1RL) monoclonal antibody targeting the IL-33 receptor. Melrilimab has the potential to be used in asthma research. MW: 145.2 KD. | Human IgG2SA |
| A2707 | Anti-MPL / TPOR / CD110 (TA136) | Anti-MPL / TPOR / CD110 (TA136) is antibody binds to MPL and recognizes a tertial structure of MPL. It can be potentially used in the treatment of congenital amegakaryocytic thrombocytopenia. MW: 143.58 KD. | Human IgG1 |
| A2964 | Avizakimab (Anti-IL-21) | Avizakimab (Anti-IL-21) is a humanised immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that targets Interleukin-21. MW: 145.42 KD. | Human IgG1 |
| A2709 | Anti-GPR44 / PTGDR2 / CD294 | Anti-GPR44 / PTGDR2 / CD294 is a monoclonal antibody against a transmembrane G-protein-coupled receptor (GPR44, also known as CRTH2, PTGDR2, or CD294) with the potential to treat asthma. MW: 147.66 KD. | Human IgG1 |
| A2965 | Brazikumab (Anti-IL-23) | Brazikumab (Anti-IL-23) is a human IgG2 monoclonal antibody that selectively binds the p19 subunit of IL-23, with a KD of 0.138 nM for human IL-23. Brazikumab can be used for research on Crohn's disease. MW: 144.82 KD. | Human IgG2SA |
| A2710 | Anti-GOLM1 | Anti-GOLM1 is a monoclonal antibody against Golgi protein-73 (GP73, Golgi Membrane Protein 1, GOLM1) with the potential to be used in research on hepatocellular carcinoma (HCC). MW: 145.62 KD. | Human IgG1 |
| A2966 | Anti-IL-23 (LY2525623) | Anti-IL-23 (LY2525623) is a human monoclonal antibody targeting Interleukin-23 (IL-23). It has the potential to be researched for autoimmune inflammatory diseases. MW: 144.26 KD. | Human IgG1 |
| A2711 | Anti-GREM1 / Gremlin | Anti-GREM1 / Gremlin is a monoclonal antibody that binds to human gremlin-1 (GREM1) with potential anti-tumour activity. MW: 144.58 KD. | Human IgG4SP |
| A2967 | Mirikizumab (Anti-IL-23) | Mirikizumab (Anti-IL-23) is a humanised IgG4 monoclonal antibody that targets the p19 subunit of interleukin 23. Mirikizumab can be used for research on ulcerative colitis. MW: 144.26 KD. | Human IgG4SP |
| A2712 | Erlizumab (Anti-Integrin b2 / ITGB2 / CD18) | Erlizumab (anti-Integrin b2 / ITGB2 / CD18) is a humanised monoclonal antibody targeted against Integrin beta-2 and used as a therapy for haemorrhagic shock. MW: 146.66 kD. | Human IgG1 |
| A2968 | Camidanlumab (Anti-IL-2Ra / CD25) | Camidanlumab (HuMax-TAC) is a human IgG1 monoclonal antibody directed against CD25 (IL-2R alpha), which is overexpressed in a variety of haematological tumours. MW: 143.98 KD. | Human IgG1 |
| A2713 | Anti-Nogo Receptor / NgR | Anti-Nogo Receptor / NgR is a monoclonal anti-NgR antibody with the potential to promote axonal regeneration. MW: 146.18 KD. | Human IgG2SA |
| A2969 | Ocaratuzumab (Anti-CD20) | Ocaratuzumab (anti-CD20) is an Fc-engineered monoclonal antibody directed against human CD20 with potential antineoplastic activity. Ocaratuzumab exhibits more effective antibody-dependent cell-mediated cytotoxicity (ADCC). MW: 145.38 kD. | Human IgG1 |
| A2714 | Anti-Complement Factor P / Properdin | Anti-Complement Factor P / Properdin is a monoclonal anti-Properdin antibody with the potential to treat chronic complement-mediated and complement-associated disorders. MW: 145.54 KD. | Human IgG1 |
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.